Search Results

CereVasc, Inc. announced today that it has received approval from the US Food and Drug Administration (FDA) to initiate its “Pivotal Study to Evaluate the Safety and Effectiveness of the CereVasc® eShunt® System in the Treatment of Normal Pressure Hydrocephalus” (STRIDE trial).

May 7, 2024

·

2 min read

Genetown

CereVasc Announces $70 Million Series B Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus

CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, announced it has successfully completed the initial closing of a $70 Million Series B financing.

May 13, 2024

·

2 min read

Genetown

CereVasc’s eShunt® System Study Data Presented at the ABC WIN Seminar

CereVasc, Inc. announced that data from its clinical studies in the United States and Argentina, examining the use of its eShunt System to treat communicating hydrocephalus, was presented at the ABC WIN Seminar in Val d’Isere.

January 23, 2024

·

2 min read

Press Releases

CereVasc Announces Appointments of New Directors

July 16, 2024

·

3 min read

Genetown

CereVasc’s eShunt™ System to be Presented at the International Stroke Conference by Dr. Pedro Lylyk

CereVasc, Inc. announced that Dr. Pedro Lylyk, Director General of ENERI, will deliver a symposium presentation entitled, “Endovascular Shunting for Hydrocephalus After Subarachnoid Hemorrhage and Other Applications,” at the International Stroke Conference in Phoenix, Arizona on Wednesday, February 7th.

February 7, 2024

·

2 min read